These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 37668153)

  • 1. Emerging oral drug options for ulcerative colitis.
    Salvatori S; Neri B; Marafini I; Brigida M; Monteleone G
    Expert Opin Emerg Drugs; 2023 Dec; 28(3):191-201. PubMed ID: 37668153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonbiological therapeutic management of ulcerative colitis.
    Mezzina N; Campbell Davies SE; Ardizzone S
    Expert Opin Pharmacother; 2018 Nov; 19(16):1747-1757. PubMed ID: 30220228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigational cytokine-targeted therapies for ulcerative colitis.
    Monteleone G; Pallone F; Caprioli F
    Expert Opin Investig Drugs; 2013 Sep; 22(9):1123-32. PubMed ID: 23802627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ulcerative colitis: shedding light on emerging agents and strategies in preclinical and early clinical development.
    Caballol B; Gudiño V; Panes J; Salas A
    Expert Opin Investig Drugs; 2021 Sep; 30(9):931-946. PubMed ID: 34365869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive overview of novel chemical drugs for ulcerative colitis: focusing on phase 3 and beyond.
    Neri B; Mancone R; Fiorillo M; Schiavone SC; De Cristofaro E; Migliozzi S; Biancone L
    Expert Opin Pharmacother; 2024 Apr; 25(5):485-499. PubMed ID: 38591242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Filgotinib for moderately to severely active ulcerative colitis.
    Mannucci A; D'Amico F; El Saadi A; Peyrin-Biroulet L; Danese S
    Expert Rev Gastroenterol Hepatol; 2022 Oct; 16(10):927-940. PubMed ID: 36278878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in pharmacotherapy for ulcerative colitis: a focus on JAK1 inhibitors.
    Goetsch A; D'Amico F; Allocca M; Fiorino G; Furfaro F; Zilli A; Parigi TL; Radice S; Peyrin-Biroulet L; Danese S
    Expert Opin Pharmacother; 2023 May; 24(7):849-861. PubMed ID: 37038911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging therapies for ulcerative colitis.
    Hanzel J; Hulshoff MS; Grootjans J; D'Haens G
    Expert Rev Clin Immunol; 2022 May; 18(5):513-524. PubMed ID: 35477319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etrolizumab for ulcerative colitis: the new kid on the block?
    Makker J; Hommes DW
    Expert Opin Biol Ther; 2016; 16(4):567-72. PubMed ID: 26914639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etrolizumab for induction of remission in ulcerative colitis.
    Rosenfeld G; Parker CE; MacDonald JK; Bressler B
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011661. PubMed ID: 26630451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vedolizumab for the treatment of ulcerative colitis.
    Shahidi N; Bressler B; Panaccione R
    Expert Opin Biol Ther; 2016; 16(1):129-35. PubMed ID: 26567768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis.
    Chande N; McDonald JW; Macdonald JK; Wang JJ
    Cochrane Database Syst Rev; 2010 Oct; (10):CD006774. PubMed ID: 20927749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis.
    Chande N; McDonald JW; Macdonald JK
    Cochrane Database Syst Rev; 2008 Apr; (2):CD006774. PubMed ID: 18425969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Algorithms to facilitate shared decision-making for the management of mild-to-moderate ulcerative colitis.
    Jackson B; De Cruz P
    Expert Rev Gastroenterol Hepatol; 2018 Nov; 12(11):1079-1100. PubMed ID: 30284911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors of the Janus Kinases: A New Oral Treatment Option for Ulcerative Colitis.
    Antonelli E; Torti G; Bassotti G
    J Clin Gastroenterol; 2019 Oct; 53(9):635-640. PubMed ID: 31373941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety of approved biologics for ulcerative colitis.
    D'Amico F; Parigi TL; Bonovas S; Peyrin-Biroulet L; Danese S
    Expert Opin Drug Saf; 2020 Jul; 19(7):807-816. PubMed ID: 32441228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tofacitinib for the treatment of ulcerative colitis.
    Izzo R; Bevivino G; Monteleone G
    Expert Opin Investig Drugs; 2016 Aug; 25(8):991-7. PubMed ID: 27177233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance therapy options for ulcerative colitis.
    Chaparro M; Gisbert JP
    Expert Opin Pharmacother; 2016 Jul; 17(10):1339-49. PubMed ID: 27240112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ustekinumab for treating ulcerative colitis: an expert opinion.
    Biancone L; Ardizzone S; Armuzzi A; Castiglione F; D'Incà R; Danese S; Daperno M; Gionchetti P; Rizzello F; Scribano ML; Vecchi M; Orlando A
    Expert Opin Biol Ther; 2020 Nov; 20(11):1321-1329. PubMed ID: 32662683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.